Hafez K S, Krishnamurthi V, Campbell S C, Novick A C
Department of Urology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Urology. 2000 Sep 1;56(3):382-6. doi: 10.1016/s0090-4295(00)00691-9.
To treat concurrent renal cell carcinoma (RCC) and renal artery disease (RAD), which pose an unusual and challenging management dilemma.
Before June 1998, 48 patients presented with localized RCC and RAD affecting all the functioning renal parenchyma. These patients were grouped into four distinct categories: group 1, a solitary kidney with RCC and RAD (n = 8); group 2, bilateral RCC and coexistent RAD (n = 9); group 3, unilateral RCC and contralateral RAD (n = 15); and group 4, unilateral RCC and bilateral RAD (n = 16). The most common cause of RAD was atherosclerosis (n = 40), followed by medial fibroplasia (n = 5), renal artery aneurysm (n = 2), and arteriovenous malformation (n = 1).
All patients underwent complete surgical excision of RCC. A nephron-sparing operation was performed preferentially (44 patients), and bilateral renal cancer operations were staged. Eleven patients underwent surgical renal vascular reconstruction in conjunction with either partial (n = 9) or radical (n = 2) nephrectomy. In 2 patients, renal revascularization was accomplished by percutaneous transluminal angioplasty before tumor excision. No perioperative deaths occurred. Postoperatively, preservation of renal function was achieved in 47 patients; 1 patient required chronic dialysis. The overall and cancer-specific 5-year patient survival rates in this series were 66% and 90%, respectively. At a mean follow-up of 58 months, 28 patients were alive with no evidence of malignancy. Six patients died of metastatic RCC, and 14 died of unrelated causes with no evidence of malignancy.
Nephron-sparing surgery combined with selective renal arterial reconstruction can yield gratifying results in this complex patient population.
治疗同时存在的肾细胞癌(RCC)和肾动脉疾病(RAD),这带来了一个特殊且具有挑战性的管理难题。
1998年6月之前,48例患者表现为局限性RCC和影响所有功能性肾实质的RAD。这些患者被分为四个不同类别:第1组,单肾合并RCC和RAD(n = 8);第2组,双侧RCC并共存RAD(n = 9);第3组,单侧RCC和对侧RAD(n = 15);第4组,单侧RCC和双侧RAD(n = 16)。RAD最常见的病因是动脉粥样硬化(n = 40),其次是中层纤维增生(n = 5)、肾动脉动脉瘤(n = 2)和动静脉畸形(n = 1)。
所有患者均接受了RCC的完整手术切除。优先进行了保留肾单位手术(44例患者),双侧肾癌手术分阶段进行。11例患者在进行部分肾切除术(n = 9)或根治性肾切除术(n = 2)的同时接受了肾血管重建手术。2例患者在肿瘤切除前通过经皮腔内血管成形术实现了肾血管再通。无围手术期死亡病例。术后,47例患者肾功能得以保留;1例患者需要长期透析。该系列患者的总体5年生存率和癌症特异性5年生存率分别为66%和90%。平均随访58个月时,28例患者存活且无恶性肿瘤证据。6例患者死于转移性RCC,14例患者死于无关原因且无恶性肿瘤证据。
保留肾单位手术联合选择性肾动脉重建术在这类复杂患者群体中可取得令人满意的结果。